Article Text
PDF
Abstract
The mechanism of action of bronchial thermoplasty (BT) treatment for patients with severe asthma is incompletely understood. This study investigated the 2.5-year impact of BT on airway smooth muscle (ASM) mass and clinical parameters by paired data analysis in 22 patients. Our findings demonstrate the persistence of ASM mass reduction of >50% after 2.5 years. Furthermore, sustained improvement in asthma control, quality of life and exacerbation rates was found, which is in line with previous reports. An association was found between the remaining ASM and both the exacerbation rate (r=0.61, p=0.04 for desmin, r=0.85, p<0.01 for alpha smooth muscle actin (SMA)) and post-bronchodilator forced expiratory volume in 1 s predicted percentage (r=−0.69, p=0.03 for desmin, r=−0.58, p=0.08 for alpha SMA). This study provides new insight into the long-term impact of BT.
- Asthma
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Introduction
Bronchial thermoplasty (BT) is a bronchoscopic treatment option for patients with severe asthma, showing clinical benefits with long-term outcomes reported up to 10 years.1 Next to clinical improvements, several studies documented reduction in the airway smooth muscle (ASM) mass after BT.2–6 Despite consistent reports demonstrating clinical improvements and ASM reduction associated with BT, a definitive relationship between BT response and histological changes has not been established.5 7 8 Only few reports with limited patient numbers have shown a correlation between the reduction in ASM mass and clinical parameters.3 9 Furthermore, long-term follow-up of ASM data over more than 2.5 years has been reported in two studies, however either performed in a small cohort4 or the ASM data were not measured in the same patients longitudinally.6
Methods
Recently, we published the TASMA randomised controlled trial (RCT)7 in which both clinical outcomes and reduction of >50% in ASM mass 0.5 year after BT were described. To investigate long-term effects, this extension study aimed to assess clinical outcomes, ASM mass and their relation 2.5 years after BT (ClinicalTrials.gov NCT02975284). In this study, participants from the Amsterdam cohort were invited to participate. Subjects were offered repeat bronchoscopy for airway histology and were monitored for clinical response at 1.5 and 2.5 years after BT. Clinical data, including annualised exacerbation rate, lung function, Asthma Control Questionnaire (ACQ) scores and Asthma Quality of Life Questionnaire (AQLQ) scores were collected. During bronchoscopy, four endobronchial biopsies were obtained, processed and stained for ASM-specific desmin and alpha smooth muscle actin (α-SMA) as previously described.7 ASM mass was expressed as percentage of positive stained area as compared with the total biopsy area.7
Endpoints of this study were to determine clinical response, including AQLQ, ACQ and annualised exacerbation rate yearly after BT aligned with ASM mass 2.5 years after BT as compared with baseline and 0.5 year after BT. Other endpoints were medication use and pulmonary function tests. Due to the COVID-19 pandemic period, some study visits had to be postponed. The first subsequent time point at which data were available was used for analyses (1.5-year study visit with a median of 1.7 years (IQR 1.6–1.8), and 2.5-study visit with a median of 2.9 years (IQR 2.7–3.3)).
Statistical analyses were performed in IBM SPSS Statistics V.28.0 and GraphPad Prism V.9.0 (GraphPad Software, San Diego, California, USA). To describe the study population, mean with SD or median with IQRs was provided. Data from the TASMA trial were used for 0.5-year analysis. The comparison between time points was calculated with paired t-tests or Wilcoxon signed-rank test depending on the distribution of variables. Spearman’s correlation was used to explore associations between clinical outcomes and histology. All tests were two sided, and the level of significance was set to 0.05.
Results
From the Amsterdam TASMA cohort, 22 patients (85%) were included. Reasons for exclusion were declining to participate (n=2), loss of follow-up (n=1) and start of biological treatment (n=1). Sustained improvements were observed in ACQ score (p<0.01), AQLQ score (p<0.01) and exacerbation rate (p=0.01) 2.5 years after BT as compared with baseline (table 1). The observed reduction in ASM area at 0.5 year persisted at 2.5-year follow-up. Desmin analysis showed 10.05% area of the total biopsy surface at baseline, 4.93% area 0.5 year after BT and 3.70% area 2.5 years post-BT. The α-SMA analysis showed a comparable reduction: 20.54% area at baseline, 13.16% area 0.5 year after BT and 10.21% area 2.5 years post-BT (table 1 and figure 1). Associations were explored between ASM content with clinical characteristics at baseline, 2.5 years post-BT and between the delta (defined as post-BT minus pre-BT values). ASM at baseline and ASM delta were not associated with clinical parameters, nor with changes in clinical parameters. A positive association was found at 2.5 years after BT between remaining ASM mass at 2.5 years after BT and the exacerbation rate (r=0.61, p=0.04 for desmin, r=0.85, p<0.01 for α-SMA). A negative association was found between post-bronchodilator forced expiratory volume in 1 s predicted percentage (FEV1%predicted) and desmin-stained ASM (r=−0.69, p=0.03) and a trend with α-SMA-stained ASM (r=−0.58, p=0.08).
Clinical characteristics and ASM mass before and after bronchial thermoplasty (BT) (n=22)
The graphs show (A) the ASM desmin% area and (B) alpha actin% area data expressed as medians (IQRs) of 12 patients with asthma. Examples of biopsies showing ASM mass stained by desmin and alpha actin at baseline, 0.5 year post-BT and 2.5 years post-BT. P values are given between baseline and 0.5 year post-BT and between baseline and 2.5 years post-BT and calculated with the Wilcoxon signed-rank test. ASM, airway smooth muscle; BT, bronchial thermoplasty.
Discussion
To the best of our knowledge, this study is the first study that investigated the 2.5-year impact of BT on clinical outcomes and ASM by paired data analysis. Our findings demonstrate persistent clinical efficacy coincided with a reduction in the ASM mass until 2.5 years after-BT as compared with baseline. At this time point, a reduction in response to a bronchoconstrictor was found, which is in line with a recent study of Henry et al.10 Next to this, 2.5 years after BT, remaining ASM mass associated positively with exacerbation rate and negatively with post-bronchodilator FEV1%predicted. Together, these findings indicate that the clinical benefits of BT involve the reduction of ASM. The association between BT-induced reductions in ASM mass and exacerbation rate in patients with severe asthma has been previously reported at 1 year after BT.3
During the TASMA trial, anti-interleukin (IL)-5 treatment was not available as standard of care. Interestingly, only one patient switched to anti-IL-5 treatment, suggesting that BT is an effective treatment option in patients with severe asthma, which may prevent costly and lifelong biological treatment. Furthermore, this study highlights improvements in quality of life, asthma control and exacerbation rates, aligning with previous RCTs and reinforcing BT’s lasting efficacy and safety.1
The strength of this study is that it provides the longest follow-up impact on ASM mass after BT by paired longitudinal analysis. Limitations are the small sample size and the fact that not all patients from the Amsterdam TASMA cohort were included in this extension study. Finally, the ASM was measured from carina biopsies and therefore provide focal information. However, studies have shown that carina measurements reflect the ASM content of the complete bronchial tree.11
In conclusion, this study reveals a consistent and enduring clinical effectiveness aligned with a decrease in ASM mass up to 2.5 years after BT compared with baseline. We found an association between the remaining ASM mass and exacerbation rate, as well as the post-bronchodilator FEV1%predicted, which provides new insight into the long-term impact of BT.
Supplemental material
Ethics statements
Patient consent for publication
Ethics approval
This study involves human participants and ethical approval was provided by the Ethical Review Committee of Amsterdam University Medical Centers, location Academic Medical Center (NL53703.018.15. 2015_163). Participants gave informed consent to participate in the study before taking part.
Acknowledgments
We thank Michael W. T. Tanck, Ir, PhD, for his statistical advice.
Supplementary materials
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Footnotes
Contributors PW, AWMG, JNSd'H, NHTtH and PS contributed to the acquisition of the data. PW contributed to the analysis and interpretation of the data and drafting the manuscript. JJTHR, EJMW, JTA and PB contributed to the conception and design of the study and the acquisition of the data. JTA and PB contributed to the analysis and interpretation of the data and editing and reviewing of the manuscript. All authors critically revised and approved the final version of the manuscript.
Funding The TASMA Study is funded by the Dutch Lung Foundation (grant number 5.2.13.064JO), the Netherlands Organization for Health Research and Development (ZonMw) (grant number 90713477) and Boston Scientific (no award/grant number).
Disclaimer Funders were not involved in data collection, analyses, decision to publish or preparation of the manuscript.
Competing interests No conflicts of interest exist for the following authors—PW, AWMG, JNSd'H, NHTtH, JJTHR, TM, EJMW and PS. JTA reports research grants from Boston Scientific during the conduct of the study. PB reports research grants from Boston Scientific, non-financial support from Boston Scientific related to investigator-initiated research grant, research grants from ZonMw and research grants from Dutch Lung Foundation, during the conduct of the study.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.